- Home
- PPSI vs ACRV Comparison
PPSI vs ACRV Comparison
Compare PPSI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPSI
- ACRV
- Stock Information
- Founded
- PPSI 2008
- ACRV 2018
- Country
- PPSI United States
- ACRV United States
- Employees
- PPSI N/A
- ACRV N/A
- Industry
- PPSI Electrical Products
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- PPSI Industrials
- ACRV Health Care
- Exchange
- PPSI Nasdaq
- ACRV Nasdaq
- Market Cap
- PPSI 40.2M
- ACRV 41.7M
- IPO Year
- PPSI N/A
- ACRV 2022
- Fundamental
- Price
- PPSI $3.66
- ACRV $1.33
- Analyst Decision
- PPSI Strong Buy
- ACRV Buy
- Analyst Count
- PPSI 1
- ACRV 7
- Target Price
- PPSI $12.00
- ACRV $17.40
- AVG Volume (30 Days)
- PPSI 5.1M
- ACRV 213.8K
- Earning Date
- PPSI 08-14-2025
- ACRV 08-13-2025
- Dividend Yield
- PPSI 41.15%
- ACRV N/A
- EPS Growth
- PPSI N/A
- ACRV N/A
- EPS
- PPSI 2.91
- ACRV N/A
- Revenue
- PPSI $31,279,000.00
- ACRV N/A
- Revenue This Year
- PPSI $24.01
- ACRV N/A
- Revenue Next Year
- PPSI $19.25
- ACRV $1,037.93
- P/E Ratio
- PPSI $1.25
- ACRV N/A
- Revenue Growth
- PPSI 105.82
- ACRV N/A
- 52 Week Low
- PPSI $2.25
- ACRV $1.05
- 52 Week High
- PPSI $7.00
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- PPSI 56.20
- ACRV 51.00
- Support Level
- PPSI $3.52
- ACRV $1.27
- Resistance Level
- PPSI $3.80
- ACRV $1.42
- Average True Range (ATR)
- PPSI 0.36
- ACRV 0.08
- MACD
- PPSI 0.02
- ACRV 0.00
- Stochastic Oscillator
- PPSI 23.60
- ACRV 55.32
About PPSI Pioneer Power Solutions Inc.
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.